celecoxib has been researched along with Glial Cell Tumors in 25 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease." | 9.11 | Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. ( Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J, 2005) |
| "A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)." | 7.81 | Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015) |
| "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model." | 7.73 | Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. ( Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K, 2006) |
| " To determine whether oral administration of a COX-2-specific inhibitor can inhibit glial tumors, we analyzed the effect of celecoxib on the growth of 9L rat gliosarcoma cells that were orthotopically transplanted into rat brains." | 7.72 | Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. ( Eoh, W; Hong, SC; Im, YH; Kim, JH; Kim, MH; Lee, S; McDonnell, TJ; Nam, DH; Park, C; Park, K; Shin, HJ, 2004) |
| "Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas." | 5.42 | Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. ( Winfield, LL; Yerokun, T, 2015) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | 5.40 | Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Malignant gliomas are heavily infiltrated by immature myeloid cells that mediate immunosuppression." | 5.40 | Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. ( Kosaka, A; Ohkuri, T; Okada, H, 2014) |
| "Malignant gliomas have low survival expectations regardless of current treatments." | 5.39 | Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib. ( Grimaldi, M; Hobrath, JV; Johnson, GG; Piazza, GA; White, MC; Zhang, W, 2013) |
| "In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease." | 5.11 | Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. ( Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J, 2005) |
| "A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)." | 3.81 | Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015) |
| "The selective COX-2 inhibitors NS-398, Celecoxib and Meloxicam and three human glioma cell lines (D384, U251 and U87) were used." | 3.74 | Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. ( Berg, Jv; Kuipers, GK; Lafleur, MV; Slotman, BJ; Sminia, P; Stoter, TR; Wedekind, LE, 2007) |
| "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model." | 3.73 | Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. ( Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K, 2006) |
| " To determine whether oral administration of a COX-2-specific inhibitor can inhibit glial tumors, we analyzed the effect of celecoxib on the growth of 9L rat gliosarcoma cells that were orthotopically transplanted into rat brains." | 3.72 | Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. ( Eoh, W; Hong, SC; Im, YH; Kim, JH; Kim, MH; Lee, S; McDonnell, TJ; Nam, DH; Park, C; Park, K; Shin, HJ, 2004) |
| "Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas." | 1.42 | Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. ( Winfield, LL; Yerokun, T, 2015) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | 1.40 | Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Malignant gliomas are heavily infiltrated by immature myeloid cells that mediate immunosuppression." | 1.40 | Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. ( Kosaka, A; Ohkuri, T; Okada, H, 2014) |
| "Malignant gliomas have low survival expectations regardless of current treatments." | 1.39 | Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib. ( Grimaldi, M; Hobrath, JV; Johnson, GG; Piazza, GA; White, MC; Zhang, W, 2013) |
| "Celecoxib was incorporated into poly DL-lactide-co-glycolide (PLGA) nanoparticles for antitumor drug delivery." | 1.37 | Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells. ( Jeong, YI; Jin, SG; Jung, S; Jung, TY; Kang, SS; Kim, IY; Kim, TH; Moon, KS; Pei, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, B | 1 |
| Guo, ZS | 1 |
| Bartlett, DL | 1 |
| Yan, DZ | 1 |
| Schane, CP | 1 |
| Thomas, DL | 1 |
| Liu, J | 1 |
| McFadden, G | 1 |
| Shisler, JL | 1 |
| Roy, EJ | 1 |
| Uram, Ł | 1 |
| Markowicz, J | 1 |
| Misiorek, M | 1 |
| Filipowicz-Rachwał, A | 1 |
| Wołowiec, S | 1 |
| Wałajtys-Rode, E | 1 |
| Zhang, H | 1 |
| Tian, M | 1 |
| Xiu, C | 1 |
| Wang, Y | 1 |
| Tang, G | 1 |
| Xu, K | 2 |
| Wang, L | 1 |
| Shu, HK | 2 |
| Porkholm, M | 1 |
| Valanne, L | 2 |
| Lönnqvist, T | 2 |
| Holm, S | 1 |
| Lannering, B | 1 |
| Riikonen, P | 2 |
| Wojcik, D | 1 |
| Sehested, A | 1 |
| Clausen, N | 1 |
| Harila-Saari, A | 1 |
| Schomerus, E | 1 |
| Thorarinsdottir, HK | 1 |
| Lähteenmäki, P | 1 |
| Arola, M | 1 |
| Thomassen, H | 1 |
| Saarinen-Pihkala, UM | 2 |
| Kivivuori, SM | 2 |
| Kosaka, A | 1 |
| Ohkuri, T | 1 |
| Okada, H | 2 |
| Kerschbaumer, J | 1 |
| Schmidt, FA | 1 |
| Grams, AE | 1 |
| Nowosielski, M | 1 |
| Pinggera, D | 1 |
| Brawanski, KR | 1 |
| Petr, O | 1 |
| Thomé, C | 1 |
| Tuettenberg, J | 1 |
| Seiz, M | 1 |
| Freyschlag, CF | 1 |
| Wickström, M | 1 |
| Dyberg, C | 1 |
| Milosevic, J | 1 |
| Einvik, C | 1 |
| Calero, R | 1 |
| Sveinbjörnsson, B | 1 |
| Sandén, E | 1 |
| Darabi, A | 1 |
| Siesjö, P | 1 |
| Kool, M | 1 |
| Kogner, P | 1 |
| Baryawno, N | 1 |
| Johnsen, JI | 1 |
| Yerokun, T | 1 |
| Winfield, LL | 1 |
| Ju, RJ | 1 |
| Zeng, F | 1 |
| Liu, L | 1 |
| Mu, LM | 1 |
| Xie, HJ | 1 |
| Zhao, Y | 1 |
| Yan, Y | 1 |
| Wu, JS | 1 |
| Hu, YJ | 1 |
| Lu, WL | 1 |
| Sato, A | 1 |
| Mizobuchi, Y | 1 |
| Nakajima, K | 1 |
| Shono, K | 1 |
| Fujihara, T | 1 |
| Kageji, T | 1 |
| Kitazato, K | 1 |
| Matsuzaki, K | 1 |
| Mure, H | 1 |
| Kuwayama, K | 1 |
| Sumi, A | 1 |
| Saya, H | 1 |
| Sampetrean, O | 1 |
| Nagahirao, S | 1 |
| Kim, CK | 1 |
| Joe, YA | 1 |
| Lee, SK | 1 |
| Kim, EK | 1 |
| O, E | 1 |
| Kim, HK | 1 |
| Oh, BJ | 1 |
| Hong, SH | 1 |
| Hong, YK | 1 |
| Zhou, R | 1 |
| Zhang, LZ | 1 |
| Wang, RZ | 1 |
| Nakano, I | 1 |
| Chiocca, EA | 1 |
| Gao, H | 1 |
| Fujita, M | 1 |
| Kohanbash, G | 1 |
| Fellows-Mayle, W | 1 |
| Hamilton, RL | 1 |
| Komohara, Y | 1 |
| Decker, SA | 1 |
| Ohlfest, JR | 1 |
| Kim, TH | 1 |
| Jeong, YI | 1 |
| Jin, SG | 1 |
| Pei, J | 1 |
| Jung, TY | 1 |
| Moon, KS | 1 |
| Kim, IY | 1 |
| Kang, SS | 1 |
| Jung, S | 1 |
| White, MC | 1 |
| Johnson, GG | 1 |
| Zhang, W | 1 |
| Hobrath, JV | 1 |
| Piazza, GA | 1 |
| Grimaldi, M | 1 |
| Nam, DH | 2 |
| Park, K | 2 |
| Park, C | 1 |
| Im, YH | 1 |
| Kim, MH | 1 |
| Lee, S | 1 |
| Hong, SC | 1 |
| Shin, HJ | 1 |
| Kim, JH | 1 |
| Eoh, W | 1 |
| McDonnell, TJ | 1 |
| Reardon, DA | 1 |
| Quinn, JA | 1 |
| Vredenburgh, J | 1 |
| Rich, JN | 1 |
| Gururangan, S | 1 |
| Badruddoja, M | 1 |
| Herndon, JE | 1 |
| Dowell, JM | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Eichele, K | 1 |
| Weinzierl, U | 1 |
| Ramer, R | 1 |
| Brune, K | 1 |
| Hinz, B | 1 |
| Kang, SG | 1 |
| Kim, JS | 2 |
| Groves, MD | 1 |
| Kesari, S | 1 |
| Schiff, D | 1 |
| Doherty, L | 1 |
| Gigas, DC | 1 |
| Batchelor, TT | 1 |
| Muzikansky, A | 1 |
| O'Neill, A | 1 |
| Drappatz, J | 1 |
| Chen-Plotkin, AS | 1 |
| Ramakrishna, N | 1 |
| Weiss, SE | 1 |
| Levy, B | 1 |
| Bradshaw, J | 1 |
| Kracher, J | 1 |
| Laforme, A | 1 |
| Black, PM | 1 |
| Folkman, J | 1 |
| Kieran, M | 1 |
| Wen, PY | 1 |
| Kuipers, GK | 1 |
| Slotman, BJ | 1 |
| Wedekind, LE | 1 |
| Stoter, TR | 1 |
| Berg, Jv | 1 |
| Sminia, P | 1 |
| Lafleur, MV | 1 |
2 trials available for celecoxib and Glial Cell Tumors
| Article | Year |
|---|---|
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Brain Neoplasm | 2005 |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2007 |
23 other studies available for celecoxib and Glial Cell Tumors
| Article | Year |
|---|---|
Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Topics: Animals; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2 I | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cancer Vaccines; Celecoxib; Cell Line, T | 2013 |
COX-2 overexpression increases malignant potential of human glioma cells through Id1.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygen | 2014 |
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studi | 2014 |
Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD40 Antigens; Cele | 2014 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Celecoxib; Cell Lin | 2015 |
Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neopl | 2016 |
Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cycloox | 2017 |
Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain N | 2010 |
Effect of celecoxib on proliferation, apoptosis, and survivin expression in human glioma cell line U251.
Topics: Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibito | 2010 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neop | 2011 |
Finding drugs against CD133+ glioma subpopulations.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Combined Modality Th | 2011 |
Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.
Topics: Animals; Celecoxib; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; Endo | 2011 |
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Topics: Alleles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; CD8-Positive T-Lymphocytes; Cele | 2011 |
Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
Topics: Acetone; Animals; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement | 2011 |
Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; Endoplasmic Reticulum Chaperon | 2013 |
Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Celecoxib; Cell Division; Cycloox | 2004 |
R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells.
Topics: Animals; Apoptosis; Arachidonic Acids; Blotting, Western; Brain Neoplasms; Caspase 3; Caspase 9; Cas | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration.
Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose | 2007 |